NeuroSense Therapeutics opened higher at $1.80, compared with its previous close of $1.78. In the last trading session, the stock traded between $1.73 and $1.83. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in NeuroSense Therapeutics is now worth
$ 43.74
Resulting in a loss of
$ 56.26 (56.26%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.73%)
Day High
$1.83
Day Low
$1.73
Day Open
$1.80
Prev Close
$1.78
Volume
28,954
1W Return
25.32%
1M Return
-48.41%
3M Return
264.33%
6M Return
111.62%
1Y Return
83.39%
Fundamentals
Market Cap ($ Mn)
3
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-6,622.02%
ROCE
-5,801.04%
EPS (TTM)
-
Investment Returns
1 Week
25.32%
1 Month
-48.41%
3 Months
264.33%
6 Months
111.62%
9 Months
74.95%
Financials
Quarterly
All values in $ Mn
0.0
Sep 23
0.0
Dec 23
0.0
Mar 24
0.0
Jun 24
0.0
Sep 24
0.0
Dec 24
Updates
3Nov
NeuroSense delays PrimeC Canada filing to March 2027 for new data
NeuroSense delays Health Canada NDS filing for PrimeC to March 2027. Delay allows inclusion of new neurofilament light chain (NfL) analysis. Revised timeline updates previous December 2026 target. Submission addresses approximately 4,000 Canadians living with ALS.
10 days ago
2Nov
HC Wainwright downgrades NeuroSense Therapeutics to Neutral
HC Wainwright & Co. downgraded NeuroSense Therapeutics from Buy to Neutral. Analyst Lander Egaña Gorroño issued the rating change. The downgrade reflects a shift in the analyst's investment stance.
10 days ago
26Oct
Neurosense Therapeutics signs deal to supply PrimeC for ALS
Neurosense Therapeutics signed a collaboration agreement for PrimeC supply. The deal targets the treatment of Amyotrophic Lateral Sclerosis (ALS). Financial terms and duration of the agreement were not disclosed.
17 days ago
19Oct
NeuroSense files US patent for traumatic brain injury treatment combo
Filed US patent for TBI treatment using ciprofloxacin and celecoxib combination. Patent protection expected to extend through 2047 if granted. Targets unmet need as no approved disease-modifying therapies exist for secondary TBI injury. Strategy aims to broaden PrimeC asset value beyond primary ALS focus.
24 days ago
3Oct
NeuroSense Therapeutics faces Nasdaq delisting risk over MVLS shortfall
NeuroSense Therapeutics received a noncompliance notice from Nasdaq on October 1, 2026. The company failed to meet the $35 million minimum market value of listed securities requirement. NeuroSense plans to appeal by requesting a hearing before the Nasdaq Hearings Panel. The company seeks additional time to regain compliance with Listing Rule 5550(b)(2).
1mo ago
28Sep
NeuroSense CFO to present at ROTH Healthcare Conference on Sept 29
NeuroSense CFO Or Eisenberg will attend the ROTH Healthcare Conference on September 29, 2026. Discussions will cover PrimeC clinical progress and regulatory strategy in Canada and the U.S. Phase 3 PARAGON trial received FDA clearance; optimized study design is underway.
